Recent advances in TGF-β signaling pathway in COVID-19 pathogenesis: A review

• Published in: Microbial pathogenesis 2025-02, Vol.199, p.107236, Article 107236
• Main Authors: Majidpour, Mahdi, Azizi, Seyed Ghader, Davodabadi, Fatemeh, Sabeti Akbar-Abad, Mahboobeh, Abdollahi, Zahra, Sargazi, Saman, Shahriari, Hossein
• Format: Article
• Language: English
• Subjects: Clinical trial; COVID-19; Pulmonary fibrosis; SARS-CoV-2; TGF-β pathway
• ISSN: 0882-4010; 1096-1208; 1096-1208
• DOI: 10.1016/j.micpath.2024.107236

The coronavirus disease 2019 (COVID-19) has resulted in approximately 7.0 million fatalities between 2019 and 2022, underscoring a pressing need for comprehensive research into its underlying mechanisms and therapeutic avenues. A distinctive feature of severe COVID-19 is the dysregulated immune response characterized by excessive activation of immune cells and the consequent cytokine storms. Recent advancements in our understanding of cellular signaling pathways have illuminated the role of Transforming Growth Factor Beta (TGF-β) as a pivotal signaling molecule with significant implications for the pathogenesis of infectious diseases, including COVID-19. Emerging evidence reveals that TGF-β signaling, when activated by viral components or secondary pathways, adversely affects diverse cell types, particularly immune cells, and lung tissue, leading to complications such as pulmonary fibrosis. In our review article, we critically evaluate recent literature on the involvement of TGF-β signaling in the progression of COVID-19. We discuss a range of pharmacological interventions, including nintedanib, pirfenidone, corticosteroids, proton pump inhibitors, and histone deacetylase inhibitors, and their potential to modulate the TGF-β pathway in the context of COVID-19 treatment. Additionally, we explore ongoing clinical trials involving mesenchymal stem cells, low-dose radiation therapy, and artemisinin derivatives to assess their impact on TGF-β levels and subsequent clinical outcomes in COVID-19 patients. This review is particularly relevant at this juncture as the global health community continues to grapple with the ramifications of the COVID-19 pandemic, highlighting the urgent need for targeted therapeutic strategies aimed at TGF-β modulation to mitigate disease severity and improve patient outcomes. [Display omitted] •COVID-19 resulted in millions of deaths worldwide, urging effective treatments.•The disease involves unregulated immune activation and severe cytokine storms.•TGF-β is a key molecule that may affect COVID-19 progression and lung health.•Drugs like nintedanib and pirfenidone target the TGF-β pathway for treatment.